Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Receivables: 2023-2025

Historic Change in Receivables for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $49,000.

  • Artiva Biotherapeutics' Change in Receivables rose 138.58% to $49,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$509,000, marking a year-over-year increase of 65.61%. This contributed to the annual value of -$1.0 million for FY2024, which is 242.82% down from last year.
  • Artiva Biotherapeutics' Change in Receivables amounted to $49,000 in Q3 2025, which was up 124.02% from -$204,000 recorded in Q2 2025.
  • Over the past 5 years, Artiva Biotherapeutics' Change in Receivables peaked at $88,000 during Q1 2025, and registered a low of -$888,000 during Q4 2023.
  • In the last 3 years, Artiva Biotherapeutics' Change in Receivables had a median value of -$204,000 in 2025 and averaged -$229,889.
  • As far as peak fluctuations go, Artiva Biotherapeutics' Change in Receivables crashed by 58.75% in 2024, and later surged by 140.93% in 2025.
  • Quarterly analysis of 3 years shows Artiva Biotherapeutics' Change in Receivables stood at -$888,000 in 2023, then skyrocketed by 50.23% to -$442,000 in 2024, then surged by 138.58% to $49,000 in 2025.
  • Its Change in Receivables was $49,000 in Q3 2025, compared to -$204,000 in Q2 2025 and $88,000 in Q1 2025.